Step Phar­ma clos­es $41M round to take en­zyme tar­get­ing lead pro­gram in­to ear­ly-stage tri­al for T cell ma­lig­nan­cies

The search for bet­ter T and B cell ther­a­pies have ab­sorbed bil­lions in R&D funds from some of the biggest drug­mak­ers in the world. A French biotech thinks it could have a hy­per-fo­cused ap­proach to T and B cell ma­lig­nan­cies, and it’s tak­ing home a de­cent-sized check to race to the clin­ic.

Step Phar­ma has bagged $41.5 mil­lion in fund­ing to take its lead CTPS1 in­hibitor in­to clin­i­cal tri­als for T cell ma­lig­nan­cies by the first quar­ter of 2022, the French biotech said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER